Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Aleksandra Zięba x
Clear All Modify Search
Open access

Aleksandra Zięba and Damian Szlachter

Abstract

The paper explores selected factors influencing the process of radicalisation leading to the use of political violence and terror by the Muslim minorities living in the European Union member states. Internal and external catalysts conditioning this process and methods of their analysis have been presented. The second section examines various counter-radicalisation and de-radicalisation efforts of the EU. The authors analysed the multidimensional European Union policy in the area of counteracting radicalisation for empowering the population and member states in preventing the radicalisation and recruitment to terrorism and emphasising the role of social partners and local authorities. Also, the promotion of good practices for combating radicalisation, developed under the auspices of the multidisciplinary Radicalisation Awareness Network (RAN) is presented.

Open access

Elzbieta Kimak, Grzegorz Dzida, Dariusz Duma, Andrzej Prystupa, Magdalena Halabis, Aleksandra Kimak, Bartosz Zieba, Iwona Kaznowska-Bystryk and Agnieszka Kowalska

ABSTRACT

The aim of the study was to examine concentrations and relationships between melatonin levels assessed at 0:200 hrs and 0:700 hrs, lipid hydroperoxide (LPO) assessed at 0:200 hrs and 0:700 hrs, and apolipoprotein (apo)AI, apoAII, apoB, high sensitivity C-reactive protein (hsCRP) and NT-proBNP, in 27 patients with chronic heart failure (CHF) (17 patients - with NYHA class II and 10 - with NYHA class III). In the study, Lipoproteins apoAI, apoAII, apoB, high sensitivity C-reactive protein (hsCRP) levels were determined by way of immunonephelometric methods, serum melatonin concentration was measured by using a competitive enzyme immunoassay technique, while serum LPO concentration was measured by using Cayman’s Lipid Hydroperoxide Assay Kit. In the study, CHF patients without acute inflammatory response demonstrated a decreased concentration of high density lipoprotein cholesterol (HDL-C), apoAI, apoAII levels, but an increased concentration of NT-proBNP, hsCRP and LPO at night, and LPO at daytime; however, the concentration of LPO at 0:700 was lower than at 0:200. Pearson’s correlation test and multiple ridge stepwise regression showed that melatonin administered at night exerts an effect on the composition of apoAI and apoAII of HDL particles, and induces decreased LPO at 0:700, but has no effect upon NT-proBNP levels in patients with NYHA class II. However, in patients with NYHA class III, melatonin administered at night induces an increase in the content of apoAII and apoAI, which further decreases hsCRP, and this, together with the administered melatonin, brings about daytime decreases in NT-proBNP and hsCRP levels. The results indicated that the content of apoAII and apoAI in HDL particles and melatonin demonstrate an anti-oxidative and anti-inflammatory effect, and together, have a cardio-protective effect on patients with advanced CHF. Hence, the results support melatonin being a cardio-protective agent. These relationships, however, need to be confirmed in further studies.